TScan Therapeutics, Inc. (TCRX) Financials

TCRX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 202.0 million 105.1 million
Dec. 31, 2025 228.8 million 105.7 million
Sept. 30, 2025 262.2 million 118.2 million
June 30, 2025 298.6 million 121.8 million

TCRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -24.3 million 2.5 million
Dec. 31, 2025 -32.2 million 2.0 million
Sept. 30, 2025 -33.9 million 3.0 million
June 30, 2025 -34.5 million 3.3 million

TCRX Net Income

No data available :(

TCRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 128.1 million 52.4 million -
Dec. 31, 2025 152.4 million 32.5 million 54.4 million
Sept. 30, 2025 184.5 million 32.4 million 56.3 million
June 30, 2025 218.0 million 32.3 million 64.4 million

TCRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 129.9 million
Dec. 31, 2025 129.9 million
Sept. 30, 2025 129.8 million
June 30, 2025 129.7 million

TCRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 70000 21.9 million 8.2 million -
Dec. 31, 2025 171000 20.0 million 5.7 million -
Sept. 30, 2025 1.4 million 31.7 million 7.7 million -
June 30, 2025 1.3 million 32.6 million 8.9 million -

TCRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 982000 693000
Dec. 31, 2025 2.6 million 723000
Sept. 30, 2025 2.5 million 767000
June 30, 2025 3.1 million -

TCRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TCRX

Price: $0.92

52 week price:
0.87
2.57

Earnings Per Share: -0.96 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 133500

Market Capitalization: 60.0 million

Links: